The tragedy of thalidomide provides a cautionary tale about the potential for birth defects resulting from fetal exposure to drugs. Thalidomide was used to treat morning sickness in pregnant women. By the time it was banned in 1962, more than 10,000 children had been born with thalidomide-induced birth defects. “Phocomelia,” wherein babies were born with […]Read More
Author: Rick Greupink
Dr. Rick Greupink holds a PharmD from the University of Groningen, the Netherlands, obtained a PhD in pharmacokinetics and drug delivery from the same university, and further specialized as a pharmacologist during postdoctoral fellowships in both clinical and pre-clinical settings in pharmaceutical industry and academia. At the Radboud University Medical Center, Dr. Greupink is faculty in the department of Pharmacology & Toxicology, where his research focuses on investigating the pharmacological roles of drug-transporting membrane proteins in barrier and excretory tissues. The aim is to better understand and predict the impact of drug transporters on clinical pharmacokinetics, drug efficacy, and drug-induced toxicity. In this context, current projects include mechanistic studies on drug disposition in pregnancy, placental transfer, accumulation and effects of small and large molecule pharmaceuticals.